about
Bioequivalence of Alendronate and Vitamin D3 in a Combination Tablet Versus Corresponding-Dose Individual Tablets in Healthy Taiwanese Volunteers, Determined Using a Novel Plasma Alendronate Assay.Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans.Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib.Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women.Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration.Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions.The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women.
P50
Q36431254-C5944812-843D-4055-9363-60B52FABDA85Q36792968-27A72FC9-C8C8-4B60-B4A3-CD1C6159FD91Q43244934-13F873AB-278B-4074-9AD3-AF732ACDB6CCQ43623556-D2D7F077-74BB-42F4-A4EA-4085070C042AQ46022677-296C78C1-9AA1-4CF8-BB8B-7A929902A20EQ47861989-B91E8292-78C9-41F2-A08B-96407B089FADQ48301397-A1C8D97D-03D3-417C-BD97-B66F015034BEQ51182200-8F7566C4-F688-4806-BB9D-3EF5FB844955Q51232526-9C8B3F63-303A-4F25-AC5D-5EBE745B5381Q51770566-92307D33-87E6-4EDA-91FD-6A83FAC4F2FDQ53063255-71FC91EA-E484-4C0E-8412-8E967C806500
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stefan Zajic
@ast
Stefan Zajic
@en
Stefan Zajic
@es
Stefan Zajic
@nl
Stefan Zajic
@sl
type
label
Stefan Zajic
@ast
Stefan Zajic
@en
Stefan Zajic
@es
Stefan Zajic
@nl
Stefan Zajic
@sl
prefLabel
Stefan Zajic
@ast
Stefan Zajic
@en
Stefan Zajic
@es
Stefan Zajic
@nl
Stefan Zajic
@sl
P106
P1153
34875917400
P21
P31
P496
0000-0002-9844-9951